TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > The importance of Quality System Audits

The importance of Quality System Audits

Maintaining regulatory compliance is critical to ensuring the continuity of your operations

Whether your organization is virtual or fully in-house, conducting audits is an essential component of a good quality system in order to evaluate the effectiveness of the quality system,  maintain regulatory compliance and ultimately ensure patient safety.

ICH Q10, section 1.5  states that the implementation of the Q10 quality management system model should result in achievement of three main objectives where auditing plays a critical role in all three objectives detailed below:

  • Achieve product realisation
  • Establish and maintain a state of control
  • Facilitate continual improvement

The ICH Q10 document can be viewed at the following link:

https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human_en.pdf

  • In order to achieve product realization, appropriate quality materials must be purchased from approved suppliers. Section 2.7 of ICH Q10 states that the pharmaceutical company is ‘ultimately responsible to ensure processes are in place to assure the control of outsourced activities and quality of purchased materials.’ Prior to selecting material suppliers or outsourcing operations, the suitability of the outsourced party to carry out the activity must be assessed. Suppliers must be approved before being used and audits are one means of evaluating both suppliers and outsourced operations. The method for assessing a supplier or an outsourced operation should be defined in a procedure. The procedure should clearly define when an audit is required or when an alternative evaluation method is acceptable. ICH Q9 provides guidance on the principles and tools of quality risk management that can be performed to determine the type of evaluation to be used i.e. if the operation is high risk then the output of the risk assessment may deem an audit necessary.

The ICH Q9 document can be viewed at the following link:

https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-     harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-3.pdf

The procedure should also specify how the frequency of the audits will be determined and how the operations to be audited are determined.  The audit frequency and schedules should be risk based and all aspects of the quality system should be audited annually.   The key focus of an audit of a supplier or outsourced operation should be whether the supplier or outsourced operation has a quality system in place and the effectiveness of the quality system.   The main purpose of the evaluation is to ensure that the supplier or outsourced operation can provide the material or products meeting their quality specifications and requirements.

 

  • Establishment and maintenance of a state-of-control requires periodic reviews of operations and periodic reviews can be achieved by conducting audits of these operations and processes. The management review system should include the review of the audit results as part of the periodic review of the quality system. Management must be made aware of any audit observations which impact the quality system as they are responsible for ensuring the effectiveness of the quality system and to ensure a state of control is maintained. An effective monitoring system provides assurance of the capability of the processes to produce a product of the desired quality. The methods for continuous monitoring may vary depending on risk assessments which may include periodic audits and monitoring of regulatory findings.

 

  • In order to facilitate continual improvement, management should review internal and external audit results and act upon the findings as part of the continuous improvement process. ICH Q10, section 4.3  lists the following as potential outcomes of the management reviews:
  • ‘Improvements to the pharmaceutical quality system and related processes
  • Allocation or reallocation of resources and/or personnel training
  • Revisions to quality policy and quality objectives
  • Documentation and timely and effective communication of the results of the management review and actions, including escalation of appropriate issues to senior management.’

An effective audit programme can play an integral role in product realization, process performance and quality monitoring and continuous improvement within a quality management system. The use of quality risk management as defined in ICH Q9 provides useful tools for prioritising audits. Companies should examine their auditing programmes to ensure the key objectives as defined in ICH Q10 are being met.

PharmaLex has built up a wealth of expertise over the years and has a proven record in the ability to deliver audits, internally and externally, in line with their company motto: “Confidence beyond Compliance”. PharmaLex has a team of GxP consultants that come from a wide variety of backgrounds who can perform audits in compliance to global GxP regulations. This allows for maximum flexibility to provide technically suitable and centrally located auditors for each audit when needed.  Audits are conducted using a “hat-on/hat-off” approach in which the auditor provides feedback to the auditee during the audit. This real-time mentoring improves auditee performance, preparedness and confidence for upcoming GxP inspections. PharmaLex auditors provide piece of mind auditing; they are responsible for all audit preparation, onsite auditing, and audit reporting.  Following the audit, PharmaLex can support post-audit activities such as CAPAs and remediation activities to closure.

If you would like advice or support in relation to the development, improvement or execution of an audit management programme why not get in touch to find out more on the range of services that we offer and how we can help you by connecting with us on +353 1 846 4742 or email us at contact@pharmalex.com

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Highly competent, knowledgeable, absolutely reliable and dedicated to the projects

    Europe based medium-sized biotech development company
    Senior Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for